ArticleAesthetic plastic surgery2026
The Effective Delivery of Poly(D,L-lactic Acid) (Juvelook) via Needle-Free Injection (CUREJET) for Facial Rejuvenation.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly(D,L-lactic acid) (PDLLA) is increasingly used for skin rejuvenation, utilizing innovative delivery systems like needle-free injectors to enhance patient comfort and efficacy.
objectiveTo evaluate the clinical efficacy and safety of PDLLA delivered through a microjet injector and to assess the durability of its rejuvenating effect over 24 weeks.
methodsThis study involved 40 patients who underwent five treatment sessions of PDLLA (Juvelook) treatment via a needle-free microjet system. Efficacy was assessed through clinical evaluation (GAIS), patient satisfaction surveys, and 3D imaging analysis at baseline, 8 weeks, and 24 weeks.
resultsGAIS scores improved from 1.48 ± 0.32 at baseline to 1.90 ± 0.28 at 8 weeks and 2.16 ± 0.26 at 24 weeks (p < 0.001). Patient satisfaction increased from 3.38 ± 1.12 to 7.95 ± 0.86 (8 weeks) and 8.71 ± 0.69 (24 weeks). 3D imaging showed progressive vector displacement, with a mean displacement of 1.5 ± 0.4 mm at 8 weeks and 2.3 ± 0.5 mm at 24 weeks, indicating sustained lifting and textural improvement. These effects are attributed to the high-velocity microjet delivery mechanism, which enables uniform intradermal dispersion with minimal trauma.
conclusionPDLLA (Juvelook) delivered via needle-free injection (CUREJET, BAZ BIOMEDIC CO., LTD.) is a safe and effective modality for facial rejuvenation, offering a promising alternative to conventional methods. Further research is needed to explore long-term outcomes and mechanistic insights. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41389157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.